ArticleJournal of virology2008
Neutralizing antibody blocks adenovirus infection by arresting microtubule-dependent cytoplasmic transport.
Article in Journal of virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 66 citations in OpenAlex.
- The seroprevalence of adenoviruses since 2000Emerging microbes & infections · 2025Review
- Neutralizing monoclonal antibodies protect against human adenovirus type 55 infection in transgenic mice and tree shrews.Emerging microbes & infections · 2024Article
- Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses.Journal of microbiology (Seoul, Korea) · 2024Review
- Review
- Significance of Preexisting Vector Immunity and Activation of Innate Responses for Adenoviral Vector-Based Therapy.Viruses · 2022Review
- Adenovirus entry: Stability, uncoating, and nuclear import.Molecular microbiology · 2022Review
- Therapeutic Implementation of Oncolytic Viruses for Cancer Immunotherapy: Review of Challenges and Current Clinical Trials.Journal of biomedical science and research · 2022Article
- Role of Adenoviruses in Cancer Therapy.Frontiers in oncology · 2022Review
- Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy.Cancers · 2021Review
- Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.Journal for immunotherapy of cancer · 2021Review
- Review
- Nup358 and Transportin 1 Cooperate in Adenoviral Genome Import.Journal of virology · 2020Article
- Extracellular vesicles provide a capsid-free vector for oncolytic adenoviral DNA delivery.Journal of extracellular vesicles · 2020Article
- Efficacy of a new oncolytic adenovirus armed with IL-13 against oral carcinoma models.OncoTargets and therapy · 2019Article
- Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding.Virology · 2018Article
- Identification of a Critical and Conformational Neutralizing Epitope in Human Adenovirus Type 4 Hexon.Journal of virology · 2018Article
- Small-size recombinant adenoviral hexon protein fragments for the production of virus-type specific antibodies.Virology journal · 2017Article
- Surveillance for Intracellular Antibody by Cytosolic Fc Receptor TRIM21.Antibodies (Basel, Switzerland) · 2016Review
- Transduction of skin-migrating dendritic cells by human adenovirus 5 occurs via an actin-dependent phagocytic pathway.The Journal of general virology · 2016Article
- Immune-Complexed Adenovirus Induce AIM2-Mediated Pyroptosis in Human Dendritic Cells.PLoS pathogens · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Neutralizing antibodies are commonly elicited by viral infection. Most antibodies that have been characterized block early stages of virus entry that occur before membrane penetration, whereas inhibition of late stages in entry that occurs after membrane penetration has been poorly characterized. Here we provide evidence that the neutralizing antihexon monoclonal antibody 9C12 inhibits adenovirus infection by blocking microtubule-dependent translocation of the virus to the microtubule-organizing center following endosome penetration. These studies identify a previously undescribed mechanism by which neutralizing antibodies block virus infection, a situation that may be relevant for other nonenveloped viruses that use microtubule-dependent transport during cell entry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.